Daniel R. Passeri Purchases 30,000 Shares of Cue Biopharma, Inc. (NASDAQ:CUE) Stock

Cue Biopharma, Inc. (NASDAQ:CUE) CEO Daniel R. Passeri purchased 30,000 shares of the firm’s stock in a transaction on Monday, December 16th. The stock was bought at an average price of $1.03 per share, for a total transaction of $30,900.00. Following the acquisition, the chief executive officer now owns 164,578 shares in the company, valued at $169,515.34. The trade was a 22.29 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

Cue Biopharma Price Performance

Cue Biopharma stock opened at $1.02 on Friday. The company has a quick ratio of 2.22, a current ratio of 2.22 and a debt-to-equity ratio of 0.05. The firm has a market capitalization of $64.62 million, a P/E ratio of -1.13 and a beta of 1.66. The firm has a fifty day moving average of $1.31 and a 200-day moving average of $1.05. Cue Biopharma, Inc. has a 52-week low of $0.45 and a 52-week high of $3.20.

Hedge Funds Weigh In On Cue Biopharma

A number of institutional investors and hedge funds have recently added to or reduced their stakes in CUE. Point72 Asia Singapore Pte. Ltd. acquired a new position in shares of Cue Biopharma in the 2nd quarter valued at about $66,000. Good Life Advisors LLC grew its position in Cue Biopharma by 23.1% in the 3rd quarter. Good Life Advisors LLC now owns 400,000 shares of the company’s stock worth $303,000 after purchasing an additional 75,000 shares during the last quarter. Sigma Planning Corp increased its position in Cue Biopharma by 50.9% in the 3rd quarter. Sigma Planning Corp now owns 401,325 shares of the company’s stock valued at $304,000 after acquiring an additional 135,295 shares during the period. GSA Capital Partners LLP raised its stake in shares of Cue Biopharma by 5.1% during the third quarter. GSA Capital Partners LLP now owns 291,663 shares of the company’s stock valued at $221,000 after purchasing an additional 14,104 shares in the last quarter. Finally, Geode Capital Management LLC lifted its stake in shares of Cue Biopharma by 3.3% in the 3rd quarter. Geode Capital Management LLC now owns 508,827 shares of the company’s stock worth $385,000 after acquiring an additional 16,371 shares during the period. 35.04% of the stock is owned by hedge funds and other institutional investors.

About Cue Biopharma

Cue Biopharma, Inc, a clinical-stage biopharmaceutical company, develops a novel class of injectable therapeutics to selectively engage and modulate targeted, disease relevant T cells directly within the patient's body. Its lead drug product candidate is CUE-101 for the treatment of human papilloma virus (HPV16+)-driven recurrent/metastatic head and neck cancer.